Minard-Colin V, Aupérin A, Pillon M, Burke A, Barkauskas D, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard C, Zsíros J, Csoka M, Kazanowska B, Chiang A, Patte C,*Gross TG, *on behalf of the European Intergroup for Childhood Non-Hodgkin’s lymphoma (EICNHL) and the Children’s Oncology Group (COG). Rituximab in children and adolescents with high-risk mature B-cell non-Hodgkin’s lymphoma/leukaemia: Final results of the Inter-B-NHL ritux 2010 trial. New Engl J Med 382::2207-19, 2020.

Atun R*, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, Lam CG, Ward Z, Yeh J, Allemani C, Coleman M, di Carlo V, Loucaides E, Fitchett E, Girardi F, Horton S, Steliarova-Foucher E, Sullivan R, Aitken J, Banavali S, Binagwaho A, Alcasabas P, Antillon F, Arora R, Barr RD, Bouffet E, Challinor J, Fuentes S, Gross T, Hagander L, Hoffman R, Herrera C, Kutluk T, Marcus K, Moreira C, Pritchard-Jones K, Ramirez Lorna Renner O, Robison LL, Shalkov J, Sung L, Yeoh Y, Rodriguez-Galindo C*. Lancet Oncology Commission on Sustainable Care for Children with Cancer. Lancet Oncol. 21:e185-e224, 2020.

Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Castillo L, Israels T, Sharif M, Jeha S, Sullivan M, Banavali B, Chong QT, Pui C-H, Barr R, Gross T. Towards the Cure of All Children with Cancer: Pediatric Oncology as a Global Challenge, J Clin Oncol 33:3065-73, 2015.

Gross TG, Orjeula MA, Park JR, Perkins SL, Lynch JC, Cairo MS, Smith LM, Hayashi RJ. Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): Children’s Oncology Group report. Am J Transplant. 12:3069-3075, 2012.